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Abstract: In order to evaluate the influnces of IFNαon thyroid function， thyroid-
stimulating hormone (TSH)， total thyroxine (T4)， free T4， tri-iodothyronine (T3)， and 
thyroxine-binding globulin were examined in IFNαtreated 351 patients with chronic 
hepatitis C before and during therapy. As therapy， either 3 mi1ion units (MU) of human 
lymphoblastoid IFNαor 9MU of recombinant IFNα2a was administrated daily for the 
initial two weeks followed by three times a week for 22 weeks. There were nine patients 
showing thyroid dysfunction during IFNαtherapy. They consist of one relapse of Graves' 
disease， one relapse of Hashimoto thyroiditis， one development of apparent thyroid insuffi-
ciency from subclinical hypothyroidism， five cases with transient hyperthyroidism and one 
case with transient hypothyroidism. T4 and T3 levels in most patients who transiently 
developed thyroid dysfunction were normalized spontaneously after the discontinuation of 
IFNαThyroid-related autoantibodies were positive in 4 patients before IFNαtherapyand 
newly developed in one patient during therapy. Attention should be paid first to the 
previous histories of autoimmune thyroid diseases and the existence of thyroid-related 
autoantibodies for the prediction of development of thyroid dysfunction during IFNα 
therapy. In addition， serial examinations of TSH， T3 and T4 should be also necessary for 
early detection of transient thyroid dysfunction during IFNαtherapy. 
Index Terms 
chronic hepatitis C， interferon therapy， thyroid function autoimmune disease 
INTRODUCTION 
Interferon-alpha (IFNα) is known to lead to improvement in serum aminotransferase and 
liver histology in many patients with chronic hepatitis CI-3). However， IFN treatment is often 
accompanied with various adverse reactions. Besides common side effects， such as fever， chills， 
myalgia， arthralgia， fatigue， mild reversible bone marrow suppression， nausea and diarrhea， 
there are also reported exacerbations or developments of autoimmune diseases4-15). It is 
natural for IFNαtreatment to lead to such involvement with autoimmune diseases because 
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Thyroid dysfunction following alpha-interferon treatm巴ntfor chronic hepatitis C (193) 
IFNαis a potent immunomodulatory agent and known to enhance the expression of major 
histocompatibility gene complex (MHC) class 1 antigen on several cel1 types. Among the 
autoimmune diseases induced by IFNαadministration， thyroid disorders are most often 
documented4•5•10,13-15) 
In reviewing our own experience of treating 351 patients with chronic hepatitis C by IFNα， 
there were 9 patients who developed thyroid dysfunction. In this report， we describe these 9 
patients and clinical1y analyze the factors underlying for the development of thyroid dysfunc悶
tion. 
MATERIALS AND METHODS 
Since April1991， 351 patients with chronic hepatitis C were treated with IFNα. As shown 
in Table 1， they inc1ude 236 males and 115 females whose ages ranged from 18y.o. to 69y.o. 
(mean 51.5y.o.). Liver biopsies were performed in al1 patients before IFNαtherapy. As IFNα， 
either human lymphoblastoid IFNα(natural IFNα， nIFNα， SumiferonR) or recombinant 
IFNα2a (rIFNα， CanferonR) was used at doses of 3 million units (MU) or 9MU， respectively. 
IFNαwas usual1y given daily for the intial two weeks， fol1owed by three times a week for 22 
weeks. Thyroid-stimulating hormone (TSH)， total thyroxine (T4)， free T4 (fT4) ， tri-iodo-
thyronine (T3)， and thyroxine-binding globulin (TBG) were examined before and during IFNα 
therapy in order to evaluate the effects of IFNαon thyroid function. In most patients， blood 
samples were also tested serial1y for antithyroglobulin antibody (ATG) and antimicrosomal 
antibody (AMS) by hemoagglutination. 
RESULTS 
As shown in Table 2， the nine patients (six males and three females ; aged from 38y.o. to 
7ly.o.， mean 51.0y.o.) developed thyroid dysfunction during IFNαtreatment. Five had been 
treated with rIFNα， four with nIFNαThree patients developed hypothroidism and six 
patients hyperthyroidism. The results of thyroid function tests in these nine patients are 
summarized in Table 3. A brief c1inical course is given below on each patient. 
Case 1 56y.o. Female 
She had been treated with thyroxine since March， 1991 for 12 months. In that period， the 
Table l. Charact巴risticsof pati巴nts
Variable Values 
Patient number 351 
Men and women 236， 15 
Median age at start of therapy (yo) 51.5 





N atural interferon-α 204 
Recombinant interferon-"， 147 
S. Ueda， etal. 
Table 2. Clinical f巴aturesof nin巴patientswho devel-
oped thyroid dysfunction during therapy 
with int巴rferon
(194) 































































Tabl巴 3.R巴sultsof thyroid function tests in nine patients who developed thyroid 
dysfunction while being treated with IFN a! 
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elevation of ALT level and the presence of anti-HCV in serum were found. Liver biopsy was 
performed on July 28， 1992 and the liver histology showed chronic active hepatitis CCAH) 2a 
according to the European c1assification. N atural IFNαwas started on September 8. Although 
she remained in euthyroid and free from any thyroid-related symptom for 6 months without 
medication， she began to feel fatigue in the 8th week of therapy. Thyroid function tests on the 
10th week were abnormal CTSH 150 microunits CμU)/ml， T3 0.6 ng/ml， T4 1.1μg/dI). 
Thyroxine was then prescribed and the 24-week administration of IFNαwas completed 
Thyroid test CTT) and microsome test CMT) were already positive in high titers before IFN 
treatment and tended to decrease with the use of IFNαCFig. 1). 
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Case 2 44y.o. Female 
She came to us because of shortness of breath， tachycardia and fatigue in August， 1990. 
The diagnosis of Graves' disease was made. With the introduction of methyl-mercapto-
imidazol (MMI)， thyroid function returned to normal and remained in euthyroid even after the 
drug was stopped in June， 1991. She was also found to have chronic hepatitis C by blood 
examination at her first visit. Then rIFNαwas started in September， 1992 for chronic hepatitis 
C. Before IFNαtherapy， serum T3 and T4 levels were within normal ranges， but they began 
to increase and reached the hyperthyroid ranges in the 16th week of IFN therapy， when she also 
developed fatigue and tachycardia similar to the symptoms which appeared before at the 
diagnosis of Graves' disease. Thyroid function tests did not normalize during the remaining 
IFNαperiod. However， the symptoms disappeared with the prescription of a beta-blocker and 
a minor tranquilizer. Since serum T3 and T4 remained at elevated levels even after the finish 
of the 24-week IFNαtherapy， MMI was started in July， 1993. Serum T3 and T4 reached 
normal values in two months. In this case， the titer of MT increased during IFNαtherapy. In 
addition， the elevation of TSH -binding inhibitor immunoglobulin (TBII ; nornal， < 15 %) was 
observed (Fig. 2} 
Case 3 48y.o. Male 
This patient with chronic hepatitis C had a history of transfusion in 1970， when the 
resection of the upper lobe of right lung was performed. There was no history of thyroid 
disorders. Recombinant IFNαwas initiated in August， 1992. Serum T3 and T4 levels were 
normal before and the 4th week of IFN therapy. At the 8th week of therapy， he developed 
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finger tremors. Thyroid function tests at the 12th week of therapy disclosed the presence of 
hyperthyroidism. IFNαadministration was discontinued and MMI was prescribed at a daily 
dose of 5 mg for the following 20 weeks. The levels of serum thyroid hormones returned to 
normal in 4 weeks. At the 9th week after the discontinuation of IFNα， his T4 was 1.0μg/dl 
Cnormal 4.6-12.6). T3 0.6 ng/ml Cnormal 0.8-1.8) and TSH 7.0μU/ml CnormalO.3-3.5). MMI 
was stopped at this point. Thyroid function returned to nomal in 4 weeks. Thyroid-related 
autoantibodies did not appear throughout the observation period. 
Case 4 43y.o. Male 
He had no history of thyroid diseases. Thyroid functions were normal at the 4th week and 
also at the 12th week of IFN therapy. He developed finger tremors and tachycardia in the last 
month of 24-week IFNαtherapy. Thyroid function at the last week of therapy was in a 
hyperthyroid state; T4 23.2μg/ dl， T3 3.3 ng/ml， TSH < 0.05μU/ml. But these returned to 
normal without medication in 3 months. Thyroid-related autoantibodies did not develop 
Case 5 63y.o. Male 
He had been in good health until 1985， when he had a gastorectomy because of gastric 
cancer. Transfusion at that time caused chronic hepatitis C following acute hepatitis. The 24 
week administration of nIFNαwas completed safely. T3， T4， TSH were in normal ranges at 
the 5th week of therapy. N 0 symptom related to thyroid diseases was observed throughout the 
therapy period. However， blood examination of the last injection day of nIFNαdisc10sed 
elevation of TSH level (120μU/ml) and decreasing T4 and T3 levels (1.7μg/ dl and 0.6 ng/ml， 
respectively). Both results of TT and MT turned to be positive. Although no treatment was 
Thyroid dysfunction following alpha-interferon treatment for chronic hepatitis C (197) 
introduced for the correction of the hypothyroidism， serum T3 and T4 increased to normal 
levels in 3 months. 
Case 6 71y.o. Male 
He did not have previous history of thyroid diseases. Although he had positive result 
(x1600) of MT， thyroid function was normal before IFN therapy. T3 and T4 levels remained 
within normal ranges at the 4th week of therapy， but TSH level was less than 0.05μU/ml. He 
complained of fatigue and palpitations after the 6th week of therapy. Thyroid function tests 
at the 12th week of therapy showed the presence of hyperthyroidism : T4 15.8μg/ dl， T3 2.3 ng/ 
ml， TSH < 0.05μU/ml. The titer of MT was decreased to x400. IFNαwas stopped at the end 
of the 12th week of therapy. Thyroid function spontaneously returned to euthyroid in 4 weeks 
after the discontinuation of IFNα. 
Case 7 38y.o. Female 
She had no history of autoimmune diseases. She underwent 24-week administration of 
rIFNα. Thyroid function of the 4th week of therapy was normal. She noted increasing fatigue 
and finger tremors at the 12th week of therapy. Blood examination at the 24th week showed 
hyperthyroidism; T4 23.5μg/dl， T3 3.4ng/ml and TSH<0.05μU/ml. However， the 
hyperthyroidism improved after the finish of IFNα. Thyroid-related autoantibodies were not 
detected throughout the observation period. 
Case 8 48y.o. Male 
He had right nephrectomy in 1980 because of renal rupture caused by a traffic accident， but 
no history of thyroid diseases. He felt mild fatigue in the 10th week of IFNαtreatment. 
Thyroid function at the 12th week of therapy showed a slight elevation of T4 level (14.9μg/ 
dl). MT and TT were negative at that point. The T4 values were 15.7， 13.8 and 12.8μg/dl at 
the 16th， 20th and 24th week of IFNαtherapy， respectively. Soon after the finish of IFNα 
treatment， T4 level became normal. Anti-thyroglobulin antibody and anti-microsomal anti-
body were detected at the end of IFNαtherapy. 
Case 9 47y.o. Male 
Anti-thyroglobulin antibody and anti-microsomal antibody were present in serum at high 
titers before IFNαthrerapy. T3 and T4 were in normal ranges but TSH level was elevated. 
With the use of rIFNα， T3 and T4 tended to decrease and TSH rose to more than 100μU/ml. 
Therefore thyroxine was introduced at the 8th week of therapy. The 24-week IFNαtherapy 
was then completed with thyroxine replacement therapy. 
DISCUSSION 
The development of thyroid dysfunction has been reported in patients receiving IFNαfor 
long periods， and the incidence of thyroid dysfunction during IFNαtherapy has been stated 
from 0%14) to 50%13). In IFNαtreatment for chronic hepatitis C， the development of thyroid 
dysfunction was observed in 2.54)-6%15) of patients on IFNαtherapy. In our study， 9 patients 
(198) S. U巴da，et al. 
out of 351 (2.6%) developed thyroid dysfunction. However it is possible that there were not 
included some patients who have developed just transient abnormal thyroid function without 
any symptom， since thyroid function was not examined so frequently. 
The nine patients described in this report showed normal T3 and T4 levels at the start of 
IFNαtreatment. However， two patients， Case 1 and Case 2， had histories of treatment for 
Graves' and Hashimoto's disease， respectively. Both these patients relapsed into their previous 
diseases by the use of IFNα. Therefore it was strongly suggested that IFNαtherapy provoked 
underlying autoimmune thyroid diseases. Moreover， IFNαadministration might make some 
pre-clinical autoimmune disease apparent. Indeed， in Case 9， the presence of hypothyroidism 
become overt by IFNαtherapy. Then the existence of thyroid-related autoantibodies may also 
be an important clue for predicting the development of thyroid autoimmunity as well as the 
previous history. Actually， there were four patients who had thyroid-related autoantibodies 
before IFNαtherapy. Therefore we should pay attention to the susceptibilities of autoimmune 
thyroid diseases which are manifested by the previous histories and the existence of thyroid-
related autoantibodies. 
It is noteworthy that there were 4 patients， Cases 4， 6， 7 and 8， who showed transient 
hyperthyroidism during IFNαtherapy. Serum T3 and T4 levels were elevated for a limited 
period of IFNαtreatment and became normal without antithyroid agents. In addition to these 
four cases， hyperthyroidism in Case 3 was easily corrected by a minimum dose of MMI and 
followed by transient hypothyroidism. In al of these 5 cases， an excess of thyroid hormone was 
developed during IFNαperiod and the discontinuation of IFNαnormalized thyroid hormone 
levels. Two possibilities might be raised. IFNαmay induce an excessive production of thyroid 
hormone by thyroid gland or just induce a leak of preformed hormone from the gland owing to 
some inflammatory injury. The measurement of radioactive iodine uptake could be useful for 
the differentiation. Recently Berris et aP5) reported a patient who showed transient hyperthy-
roidism with very low radioactive iodine uptake， subsequently followed by a hypothyroid state， 
suggesting destructive thyroiditis. Therefore it is reasonable to consider that IFNαinitiate 
some mechanism， 
Thyroid dysfunction following alpha-interferon tr巴atmentfor chronic h巴patitisC (199) 
In conclusion， nine patients out of 351 developed thyroid dysfunction during IFNαtherapy 
for chronic hepatitis C. There were observed relapses of preexisting autoimmune thyroid 
diseases in two patients， induction of clinically aparent thyroid insufficiency in one patient with 
subclinical hypothyroidism， and transient thyroid dysfunction in six patients. The transient 
thyroid dysfunction were considered to be due to destructive thyroiditis. These results support 
the idea that interferons may play an important role in the development or recurrence of 
autoimmune thyroid diseases. Threrefore it is necessary to examine thyroid function serially 
as well as thyroid-related autoantibodies for the early detection of autoimmne thyroid dis凶
orders during IFNαtherapy for chronic hepatitis C. 
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